This “Endometrial Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly. The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body.
"Endometrial Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometrial Cancer pipeline landscape is provided which includes the disease overview and Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dostarlimab: GlaxoSmithKline
Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. The drug is in pre-registration stage of development for the treatment of Endometrial cancer.
Lenvatinib (LENVIMA): Eisai Co Ltd
LENVIMA is an orally administered kinase inhibitor with a novel binding mode that selectively inhibits the multi activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRa; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity. The drug is registered for the treatment of endometrial cancer.
There are approx. 5+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. preregistration include GlaxoSmithKline.
Route of Administration
Molecule Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endometrial Cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometrial Cancer drugs.
Geography Covered
- Global coverage
Endometrial Cancer Understanding
Endometrial Cancer: Overview
Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly. The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body.
"Endometrial Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometrial Cancer pipeline landscape is provided which includes the disease overview and Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Endometrial Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Endometrial Cancer.
Endometrial Cancer Emerging Drugs Chapters
This segment of the Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Endometrial Cancer Emerging Drugs
Dostarlimab: GlaxoSmithKline
Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. The drug is in pre-registration stage of development for the treatment of Endometrial cancer.
Lenvatinib (LENVIMA): Eisai Co Ltd
LENVIMA is an orally administered kinase inhibitor with a novel binding mode that selectively inhibits the multi activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRa; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity. The drug is registered for the treatment of endometrial cancer.
Endometrial Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Endometrial Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Endometrial Cancer
There are approx. 5+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. preregistration include GlaxoSmithKline.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Endometrial Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endometrial Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometrial Cancer drugs.
Endometrial Cancer Report Insights
- Endometrial Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Endometrial Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Endometrial Cancer drugs?
- How many Endometrial Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometrial Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endometrial Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Endometrial Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- GlaxoSmithKline
- Eisai Co Ltd
- MedImmune
- On Target Laboratories
- Sutro Biopharma
- Netris Pharma
Key Products
- Dostarlimab
- Lenvatinib
- Durvalumab
- Pafolacianine
- STRO-002
- NP137
Table of Contents
IntroductionExecutive Summary
Endometrial Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Endometrial Cancer - Analytical Perspective
In-depth Commercial Assessment
- Endometrial Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends
Endometrial Cancer Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
- Comparative Analysis
Dostarlimab: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Pafolacianine: On Target Laboratories
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
STRO 002: Sutro Biopharma
- Product Description
Research and Development
Product Development Activities
Endometrial Cancer- Market Drivers and Barriers
Endometrial Cancer- Future Perspectives and Conclusion
Endometrial Cancer Analyst Views
Endometrial Cancer Key Companies
AppendixList of Tables
Table 1 Total Products for Endometrial Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Endometrial Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- GlaxoSmithKline
- Eisai Co Ltd
- MedImmune
- On Target Laboratories
- Sutro Biopharma
- Netris Pharma
